mTOR Signaling Pathway in Antiphospholipid Syndrome: Pathogenesis and Potential Therapeutic Targets
Drug Design, Development and Therapy · 2026-04 · Volume 20 · 1-13
DOI: 10.2147/dddt.s591631 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2026-04. Verfasst von Rongxiu Huo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Guangxi Academy of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 5…. Hauptthemen laut MEDLINE: Antiphospholipid Syndrome, Signal Transduction, TOR Serine-Threonine Kinases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, Guangxi Academy of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530016, People's Republic of China.
ORCID-Profile: Xinxiang Huang
Zitieren
APA
Huo, R., Wei, C., Yang, Y., Meng, D., Yang, Y., & Huang, X. (2026). mTOR Signaling Pathway in Antiphospholipid Syndrome: Pathogenesis and Potential Therapeutic Targets. Drug Design, Development and Therapy, Volume 20, 1-13. https://doi.org/10.2147/dddt.s591631
Vancouver
Huo R, Wei C, Yang Y, Meng D, Yang Y, Huang X. mTOR Signaling Pathway in Antiphospholipid Syndrome: Pathogenesis and Potential Therapeutic Targets. Drug Design, Development and Therapy. 2026;Volume 20:1-13. doi:10.2147/dddt.s591631
BibTeX
@article{Huo2026,
author = {Huo, Rongxiu and Wei, Chengcheng and Yang, Yanting and Meng, Danli and Yang, Yang and Huang, Xinxiang},
title = {mTOR Signaling Pathway in Antiphospholipid Syndrome: Pathogenesis and Potential Therapeutic Targets},
journal = {Drug Design, Development and Therapy},
year = {2026},
volume = {Volume 20},
pages = {1--13},
doi = {10.2147/dddt.s591631}
}
EUVIMED